Melanoma Research Study
This study is for patients with successful resection of stages IIB, IIC, or III melanoma. Many patients with successfully resected melanoma relapse after surgery. The only treatment approved by the US FDA and other international regulatory agencies for these patients has limited effectiveness and frequent toxicity. Thus, new therapies are needed for these high-risk patients with melanoma.
You may qualify if the following apply to you: